MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3062% below fair value

$1.19+0.00 (0.00%)

Close on Nov 13, 2026Market cap $122.82MP/E –Yield –

MaxCyte operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

MaxCyte's operating income for the twelve months ending Sep 30, 2026 was -$33.68M. For fiscal 2025 it was -$51.90M. The highest annual figure on record is -$11.06M in fiscal 2020.

Annual operating income

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$51.90M	–
FY2024	Dec 31, 2024	-$51.20M	–
FY2023	Dec 31, 2023	-$48.30M	–
FY2022	Dec 31, 2022	-$27.36M	–
FY2021	Dec 31, 2021	-$18.19M	–
FY2020	Dec 31, 2020	-$11.06M	–
FY2019	Dec 31, 2019	-$12.42M	–

Quarterly operating income

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$6.04M	–
Q2 FY2026	Jun 30, 2026	-$10.23M	–
Q1 FY2026	Mar 31, 2026	-$6.19M	–
Q4 FY2025	Dec 31, 2025	-$11.23M	–
Q3 FY2025	Sep 30, 2025	-$14.15M	–
Q2 FY2025	Jun 30, 2025	-$14.23M	–
Q1 FY2025	Mar 31, 2025	-$12.30M	–
Q4 FY2024	Dec 31, 2024	-$12.90M	–
Q3 FY2024	Sep 30, 2024	-$14.05M	–
Q2 FY2024	Jun 30, 2024	-$11.97M	–
Q1 FY2024	Mar 31, 2024	-$12.28M	–
Q4 FY2023	Dec 31, 2023	-$8.10M	–
Q3 FY2023	Sep 30, 2023	-$13.95M	–
Q2 FY2023	Jun 30, 2023	-$13.07M	–
Q1 FY2023	Mar 31, 2023	-$13.18M	–
Q4 FY2022	Dec 31, 2022	-$6.75M	–
Q3 FY2022	Sep 30, 2022	-$7.71M	–
Q2 FY2022	Jun 30, 2022	-$8.74M	–
Q1 FY2022	Mar 31, 2022	-$4.16M	–
Q4 FY2021	Dec 31, 2021	-$4.96M	–
Q3 FY2021	Sep 30, 2021	-$2.44M	–
Q2 FY2021	Jun 30, 2021	-$4.42M	–
Q1 FY2021	Mar 31, 2021	-$6.37M	–
Q4 FY2020	Dec 31, 2020	-$2.38M	–
Q3 FY2020	Sep 30, 2020	-$2.84M	–
Q2 FY2020	Jun 30, 2020	-$2.84M	–